Compare Inovio Pharmaceuticals Inc (INO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B). The key difference: First Trust Cloud Computing ETF is far larger — about 30.9× Inovio Pharmaceuticals Inc's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and First Trust Cloud Computing ETF for 85 Days on average.
| INO | SKYY | |
|---|---|---|
Market Cap | $112.19M | $3.47B |
Volume | 3,201,278 | 176,159 |
Sector | Health | — |
52-Week High | $2.60 | $174.89 |
52-Week Low | $0.66 | $104.16 |
Typical Hold Time | 43 Days | 85 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
SKYY (First Trust Cloud Computing ETF) trades at $170.14, down 0.37% on the day but near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support and neutral oscillators. The ETF benefits from strong secular trends in cloud computing and AI adoption, with recent news highlighting institutional position adjustments and positive sector momentum.
The outlook remains positive given cloud computing's growth trajectory and AI infrastructure demand. Key risks include sector concentration and market volatility. Analyst sentiment is generally favorable, though valuation metrics are not provided in current data. The ETF's diversified exposure to cloud infrastructure positions it well for continued technology adoption trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
